Paradigm has no data anywhere near how robust it would have been if it were in the dosing study. In PAR 005, different pain scale ((KOOS not WOMAC) around 60 patients on ITT, and then another 19 in trial condition in 008.
Having it in the 002 dosing study was the ideal scenario - PAR knew it, you know it, the market knows it - heck even Mozz knows it.
Where we at?, page-701
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
28.5¢ |
Change
-0.005(1.72%) |
Mkt cap ! $99.69M | |||
| Open | High | Low | Value | Volume |
| 29.0¢ | 29.5¢ | 28.0¢ | $33.73K | 118.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 168 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 27.0¢ | 14159 | 1 |
View Market Depth
| Last trade - 15.59pm 09/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |